Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 8/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075468 | 0.92 | NPC1 (0.39) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4077908 | 0.91 | STK17B (0.40) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL3939316 | 0.90 | NPC1 (0.39) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4071195 | 0.89 | FLT1 (0.46) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4072996 | 0.89 | PIP4K2A (0.40) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4070509 | 0.89 | NPC1 (0.37) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4065656 | 0.88 | FLT1 (0.45) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL3927516 | 0.88 | FLT1 (0.36) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL13930357 | 0.87 | NPC1 (0.41) | FLT1EGFRNPC1RAB9AKDR | |
| SCHEMBL4076232 | 0.87 | AURKB (0.39) | FLT1EGFRNPC1RAB9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | FLT1 3775/4885EGFR 498/4885NPC1 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.